Investors

AIM Rule 26 Information

This area of the web site contains all information which is required to be disclosed in accordance with Rule 26 of the AIM Rules.

Shareholder Information

Other Exchanges and Trading Platforms
Shares in Issue
Significant Shareholdings
Director Shareholdings
Shares Not in Public Hands
Restrictions in Transfer of AIM Securities
UK City Code on Takeovers and Mergers

see Shareholder Information

Advisors

see Advisors

Announcements and Notifications

see News

Q&A with LungLife AI's CEO, Paul Pagano

Half-year Report For The Six Months Ended 30 June 2023

Featured News

August 16, 2024

Medicare Finalises Coverage for Molecular Risk-Stratification Testing of Indeterminate Lung Nodules

LungLife AI, Inc. (the “Company” or “LungLife”) LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, is pleased to note the publication of the finalized Local Coverage Determination (LCD) titled “Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy” (L39654), issued by the Medicare Administrative Contractor (MAC) Noridian Healthcare […]

• Read More

August 15, 2024

Half-year 2024 Notice of Results

LungLife AI, Inc.(the “Company” or “LungLife”) Notice of Results Investor Briefing LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, will announce its unaudited half-year report for the six months ended 30 June 2024 on Thursday 22 August 2024. Investor presentation Paul Pagano, Chief Executive Officer, and […]

• Read More

« Previous 1 … 3 4 5 6 7 … 36 Next »

More News